GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk and potential applications for addiction treatment.

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Both Wegovy and Ozempic are semaglutide – a drug that first entered the US market in 2017 as a diabetes medication. It was ...

Weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer a protective shield against serious conditions such as dementia and stroke, a new study has indicated. At such a ...

Mounjaro offers up to 20% weight loss – but it’s not for everyone. Learn about eligibility, alternatives and why long-term habits still matter most.

New research has found that GLP-1 drugs can substantially reduce the risk of obesity-related cancers — and they’re more effective than getting weight loss surgery.

Now, a study of 170,000 ... cancers in U.S. adults with diabetes who took these popular medications compared to those who took another class of diabetes drug not associated with weight loss. ...

Glucagon-like peptide-1 (GLP-1) agonists — weight loss medications widely used for type 2 diabetes and obesity — have been found to unexpectedly reduce alcohol consumption as a secondary benefit.

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk and potential applications for addiction treatment.

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention.. Now, a ...